

Molecular Pathology Policy, Professional

IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY

You are responsible for submission of accurate claims. This reimbursement policy is intended to ensure that you are reimbursed based on the code or codes that correctly describe the health care services provided. UnitedHealthcare Community Plan reimbursement policies use Current Procedural Terminology (CPT®*), Centers for Medicare and Medicaid Services (CMS) or other coding guidelines. References to CPT or other sources are for definitional purposes only and do not imply any right to reimbursement.

This reimbursement policy applies to all health care services billed on CMS 1500 forms and, when specified, to those billed on UB04 forms. Coding methodology, industry-standard reimbursement logic, regulatory requirements, benefits design and other factors are considered in developing reimbursement policy.

This information is intended to serve only as a general reference resource regarding UnitedHealthcare Community Plan's reimbursement policy for the services described and is not intended to address every aspect of a reimbursement situation. Accordingly, UnitedHealthcare Community Plan may use reasonable discretion in interpreting and applying this policy to health care services provided in a particular case. Further, the policy does not address all issues related to reimbursement for health care services provided to UnitedHealthcare Community Plan enrollees.

Other factors affecting reimbursement supplement, modify or, in some cases, supersede this policy. These factors include, but are not limited to: federal &/or state regulatory requirements, the physician or other provider contracts, the enrollee's benefit coverage documents, and/or other reimbursement, medical or drug policies.

Finally, this policy may not be implemented exactly the same way on the different electronic claims processing systems used by UnitedHealthcare Community Plan due to programming or other constraints; however, UnitedHealthcare Community Plan strives to minimize these variations.

UnitedHealthcare Community Plan may modify this reimbursement policy at any time by publishing a new version of the policy on this Website. However, the information presented in this policy is accurate and current as of the date of publication.

*CPT Copyright American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Table of Contents

Application	1
Policy	2
Overview	2
Reimbursement Guidelines	2
Definitions	3
Questions and Answers	4
Codes	4
Attachments	4
Resources	5
History	5

Application

This reimbursement policy applies to UnitedHealthcare Community Plan Medicaid products.

This reimbursement policy applies to services reported using the 1500 Health Insurance Claim Form (a/k/a CMS-1500) or

its electronic equivalent or its successor form. This policy applies to all products and all network and non-network physicians and other qualified health care professionals, including, but not limited to, non-network authorized and percent of charge contract physicians and other qualified health care professionals.

Policy

Overview

This policy describes the information required when claims are submitted for Molecular Pathology services utilizing Tier 1 and Tier 2 Molecular Pathology codes, Genomic Sequencing Procedures (GSP) and other Molecular Multianalyte Assay codes, Proprietary Laboratory Analysis (PLA) codes and unlisted code 81479.

All services described in this policy may be subject to additional UnitedHealthcare reimbursement policies including, but not limited to, the Clinical Laboratory Improvement Amendments (CLIA) ID Requirement Policy, the Laboratory Services Policy, and the CCI Editing Policy.

Reimbursement Guidelines

According to the American Medical Association (AMA) molecular pathology procedure code selection is typically based on the specific gene(s) that is being analyzed. Genes are described using Human Genome Organization (HUGO) approved gene names and are italicized in the code descriptors. Gene names were taken from tables of the HUGO Gene Nomenclature Committee (HGNC) at the time the CPT codes were developed.

Codes that describe tests to assess for the presence of gene variants use common gene variant names. Typically, all of the listed variants would be tested. However, these lists are not exclusive. If other variants are also tested in the analysis, they would be included in the procedure and not reported separately. The molecular pathology codes include all analytical services performed in the test (eg, cell lysis, nucleic acid stabilization, extraction, digestion, amplification, and detection).

Tier 1 molecular pathology codes represent gene-specific and genomic procedures. Molecular pathology procedures that are not specified in a Tier 1 code should be reported using either the appropriate Tier 2 code or the unlisted molecular pathology procedure code, 81479. Tier 2 molecular pathology codes are used to report procedures not listed in Tier 1 molecular pathology codes. They are arranged by level of technical resources and interpretive work by the physician or other qualified health care professional. Each Tier 2 code lists the specific analytes associated with the procedure code level.

Genomic sequencing procedures (GSPs) and other molecular multianalyte assays codes should be used when the components of the descriptor(s) are fulfilled regardless of the technique used to provide the analysis, unless specifically noted in the code descriptor. When a GSP assay includes gene(s) that is listed in more than one code descriptor, the code for the most specific test for the primary disorder sought should be reported, rather than reporting multiple codes for the same gene(s).

In addition to Tier 1, Tier 2 and GSP procedure codes, the AMA created Proprietary Laboratory Analysis (PLA) codes. Other CPT code(s), including unlisted codes, should not be used to report single or multianalyte services that may be reported with that specific PLA code. These codes encompass all analytical services required for the analysis (eg, cell lysis, nucleic acid stabilization, extraction, digestion, amplification, hybridization and detection).

Individual Tier 1 or Tier 2 codes are considered components to GSP, PLA, or unlisted codes reported for Multianalyte testing on the same specimen. Individual Tier 1 or Tier 2 codes submitted in addition to a GSP, PLA or unlisted code 81479 will be denied.

According to the AMA, code 81479, unlisted molecular pathology procedure, should only be used for a unique procedure that is not adequately addressed by any other CPT code. It should be reported only once per patient, per specimen and date of service to identify the services provided.

When multiple molecular biomarkers are tested on the same date of service it is considered to be a multianalyte panel and requires reporting with a single CPT code. The appropriate genomic sequencing procedure (GSP) code or Proprietary Laboratory Analysis (PLA) code should be submitted when multi-gene testing is performed instead of submitting the individual Tier 1 and Tier 2 codes. When a GSP or PLA does not describe the multianalyte testing performed, the unlisted CPT code 81479 may be reported to encompass all testing performed. When an unlisted CPT code is reported on the

same date of service that a GSP or PLA code is reported for multianalyte testing, only one multianalyte testing code is allowed to encompass all testing performed and the GSP or PLA code will take precedence.

Claims that have complied with notification or prior authorization requirements in UnitedHealthcare Community Plan's Genetic Testing and Molecular Prior Authorization Program satisfy the policy's requirements without further care provider action as long as they meet UnitedHealthcare Community Plan's Genetic Test Lab Registry requirements.

State Exceptions

Arizona	Per state guidelines, Arizona Medicaid is excluded from the policy.
California	State is currently not participating in prior authorization program and is excluded from policy.
Hawaii	State is currently not participating in prior authorization program and is excluded from policy.
Kansas	Per state guidelines, Kansas Medicaid is excluded from the policy.
Massachusetts	State is currently not participating in prior authorization program and is excluded from policy.
Mississippi	Per state guidelines, Mississippi Medicaid is excluded from the policy.
Ohio	State is currently not participating in prior authorization program and is excluded from policy.
Nebraska	Per state guidelines, Nebraska Medicaid is excluded from the policy.
Virginia	State is currently not participating in prior authorization program and is excluded from policy.
Washington	Per state guidelines, Washington Medicaid is excluded from the policy.
Wisconsin	State is currently not participating in prior authorization program and is excluded from policy.

Definitions

Molecular Pathology	Molecular pathology procedures are medical laboratory procedures involving the analyses of nucleic acid (i.e., DNA, RNA) to detect variants in genes that may be indicative of germline (eg, constitutional disorders) or somatic (eg, neoplasia) conditions, or to test for histocompatibility antigens (eg, HLA).
Genomic Sequencing Procedures and Other Molecular Multianalyte Assays	Genomic sequencing procedures (GSPs) and other molecular Multianalyte assays GSPs are DNA or RNA sequence analysis methods that simultaneously assay multiple genes or genetic regions relevant to a clinical situation. They may target specific combinations of genes or genetic material, or assay the exome or genome.
Proprietary Laboratory Analysis (PLA) Codes	These codes describe proprietary clinical laboratory analyses and can be either provided by a single ("sole-source") laboratory or licensed or marketed to multiple providing laboratories (eg, cleared or approved by the Food and Drug Administration [FDA]). These codes include advanced diagnostic laboratory tests (ADLTs) and clinical diagnostic laboratory tests (CDLTs) as defined under the Protecting Access to Medicare Act (PAMA) of 2014.


Questions and Answers

1	<p>Q: Can I report separate molecular pathology CPT codes in instead of a PLA CPT code?</p> <p>A: Per the AMA, when a PLA code is available to report a given proprietary laboratory service, the service should not be reported with any other CPT code(s) and other CPT code(s) should not be used to report services that may be reported with the specific PLA code.</p>
2	<p>Q: The testing for HPA1, HPA2, HPA3, and HPA4 was performed to rule out neonatal alloimmune thrombocytopenia. Would it be correct to report CPT codes 81105, 81106, 81107, and 81108 for this testing?</p> <p>A: No, multiple molecular variants tested on the same date of service are considered a multianalyte panel and requires reporting with a single CPT code. The test panel provided should be reported with the PLA (when applicable for the provider), GSP, or other MAA multiple analyte code. In the absence of an existing code, the panel of tests provided may be registered on the NIH GTR and submitted with the unlisted CPT code 81479.</p>
3	<p>Q: The testing provided overlapped two different GSP codes. Should I report both GSP codes?</p> <p>A: Only one GSP CPT code may be reported for the testing provided. The CPT guidelines for use of the GSP codes indicate when a GSP assay includes gene(s) that are listed in more than on code descriptor, the code for the most specific test for the primary disorder sought should be reported.</p>
4	<p>Q: Laboratory XYZ performed testing that fits the PLA code descriptor; however the PLA test was not marketed to Laboratory XYZ by the proprietary clinical laboratory or manufacturer. May the PLA test code be reported?</p> <p>A: No, the proprietary clinical laboratory or manufacturer may market the right to use their tests to multiple laboratories. These codes may only be reported by registered proprietary laboratory or laboratories that have the proprietary relationship with the proprietary clinical laboratory or manufacturer.</p>
5	<p>Q: When would it be appropriate to report 81479?</p> <p>A: It would be appropriate in the following scenarios:</p> <ul style="list-style-type: none"> • The single gene or analyte analyzed is not represented by an existing Tier 1 or Tier 2 code. If the analyte is not listed in the Tier 1 descriptor or under one of the Tier 2 codes, 81479 should be used. • Multiple gene variants were analyzed in a single test panel and there is not an appropriate PLA, GSP, or other MAA test code to report

Codes

81105 – 81364	Tier 1 Molecular Pathology Codes
81400 – 81408	Tier 2 Molecular Pathology Codes
81410 – 81471	Genomic Sequencing Procedures (GSP) and Other Molecular Multianalyte Assay (MAA) Codes
0001U – 0104U	Proprietary Laboratory Analysis (PLA)

Attachments: Please right-click on the icon to open the file

 Tier 1 Molecular Pathology Codes	This list contains CPT codes categorized as Tier 1 Molecular Pathology codes.
Tier 2 Molecular Pathology Codes	This list contains CPT codes categorized as Tier 2 Molecular Pathology codes.
Genomic Sequencing Procedures (GSP) Codes	This list contains CPT codes categorized as Genomic Sequencing Procedures (GSP) codes.

Proprietary Laboratory Analyses PLA Codes	This list contains CPT codes categorized as Proprietary Laboratory Analyses (PLA) codes.
--	--

Resources
American Medical Association, Current Procedural Terminology (CPT®) and associated publications and services
Centers for Medicare and Medicaid Services, CMS Manual System or other CMS publications and services

History	
3/12/2020	Policy Version Change State exceptions section: Removed reference to Louisiana Removed all files and references to Louisiana contained in the body of the policy, information has been moved to the "Louisiana Only" policy
2/21/2020	Policy Version Change Update to Reimbursement Guidelines Q&A#1 Updated
1/1/2020	Policy implemented by UnitedHealthcare Community Plan
4/26/2019	Policy approved by the Reimbursement Policy Oversight Committee